TLPH Talphera Inc.

$TLPH I don't love this chart action. The study's not going to be done for at least a couple more months (and knowing Vince, probably longer), so a dip back down to the $1 range is looking very possible.

$TLPH just by looking at the history. Prediction is that nothing will be announced for the month of October and November. It will be a party time for shorties. Buckle up

$TLPH Brunoez, when it comes to predicting time, Vince is perhaps the worst. In every conference and presentation he exaggerates the timeline, while knowing he is exaggerating. But, other than exaggerating timelines, he is doing everything right. He had the presence of mind to acquire Niyad before any other pharma got to do it. That was brilliant. Furthermore, show me one person that doesn't exaggerate abilities, and I'll show you a mythical creature.

$TLPH Nowhere in my post did I point fingers or even mention Vince's name, so I'm not really sure why you are making that association. As for timing, the last 18 patients took 23 weeks. If the rate stays the same, that would mean the final 17 patients would take 21-22 weeks = January. However, he did imply that the rate was increasing and he keeps mentioning the end of the year, so December is definitely in play.

$TLPH What could Vince do that he is not already doing? Pointing fingers is easy. It would be very normal for enrollment to drag to mid-February. Highly unlikely it takes a day longer. The hope for ending in a couple of months is just that, hope. It's possible, but not a sure thing. February is a sure thing.

$TLPH its very bizarre to have this much unawareness. There was never a drug like this that has so much potential but already been established for decades with safety and effectiveness. Essentially zero risk. Yet no spotlight or share price that matches the value. Unless im missing something, this stock could be once in a lifetime investment opportunity.

$TLPH History is not a good guide. Enrollment started terribly slow, and gradually improved. The only surprise right now would be if they're much faster than expected. Worst case scenario is that they're exactly as fast as they have been since March. This puts completion in mid February at the latest. A moderate guess would be mid November to mid January. In any case, I'm pretty sure Vince would tell us next CC how many enrollees would be left. There will be a tiny few left. So, he would be inclined to spill the beans. After all, the only goal of next CC is to convince investors and pharmas to get ready for the results.

$TLPH new power point out from September “At a comparative cost of citrate anticoagulation, the market opportunity approximates $600 million” Thats a huge update!!!!!!

$TLPH Keeping things in perspective, the XBI is down nearly 10% in the last month. Fingers crossed we've hit bottom.

$TLPH I disagree. Who is going to sell their shares on the cheap when we're only about 3 months away from completion?? That's a pretty short window with the possibility of a 2x or more gain on the horizon. I did envision a dip down to $1.00 or $1.10 immediately after the last CC due to slower than expected enrollment, but it never materialized. IMO, the closer we get to December, the odds of a big dip go way down.

$TLPH "We are obviously over 75% enrolled, so that's great...The changes that we implemented, and we had all the target profile sites up and running, and we have seen tremendous improvement and progress over past few months in terms of enrollment where we are. I think everything right now is going as planned. I feel very confident that we'll wrap this thing up before the end of the year...Shakil Aslam Chief Medical Officer, Talphera Yeah. In terms of the primary endpoint, I can say with a lot of confidence there is essentially no risk to the study. That's very, I would say, daring statement to make, and I'll tell you why. It's not a clinical endpoint per se. We're looking at activated clotting time, which is a measure of how long it takes for blood to clot. All anticoagulants, they work by slowing down the process, so it takes longer for blood to clot. That's very objective. You take a patient whose clotting time is less than 150 seconds, you give them a blood thinner

$TLPH This is what concerned me about the technicals. I see this is a failure of management (looking at you, Vince) to instill confidence that he'll ever get the study completed. Literally every time they come out with an update, it's to announce another delay. At this point, I believe they will not have it done by the end of the year.

$TLPH does the stock price of tlph have a floor under it. Just curious because both same ceo that seems to not care about share holder value. I own 43,500 share. More than I should in one stock.

$TLPH Shakil Aslam Chief Medical Officer, Talphera Yeah. In terms of the primary endpoint, I can say with a lot of confidence there is essentially no risk to the study. That's very, I would say, daring statement to make, and I'll tell you why. It's not a clinical endpoint per se. We're looking at activated clotting time, which is a measure of how long it takes for blood to clot. All anticoagulants, they work by slowing down the process, so it takes longer for blood to clot. That's very objective. You take a patient whose clotting time is less than 150 seconds, you give them a blood thinner, which is supposed to prolong their clotting time.